Highest-materiality recent filing
Amended 8-K corrects nominee: Murray W. Stewart (not Michael S. Wyzga) elected as Class III director for 2029 term.
X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing
Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.
X4 Pharmaceuticals raises ~$145.6M in public offering of common stock and warrants
Offering of 45.86M shares at $2.90/share and pre-funded warrants for 700K shares at $2.899/share.
X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart
Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.
Closed private placement of 11,040,776 shares and 48,852,772 pre-funded warrants for gross proceeds of $85M.
X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed
Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.
X4 Pharmaceuticals secures $40M equity line with Lincoln Park Capital
Company may sell up to $40M of common stock to Lincoln Park over 24 months.
Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.
Reverse stock split at 1-for-30 ratio effective 12:01 a.m. ET on April 28, 2025; shares trade split-adjusted under XFOR.
X4 Pharma stockholders approve reverse stock split; ratio 1:15 to 1:30 to be set by board
Special meeting held April 17, 2025; ~79% of outstanding shares (137.2M of 173.7M) present, forming quorum.
X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M
XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.
X4 Pharmaceuticals gets second Nasdaq compliance period until Aug 11, 2025 for bid price rule
Closing bid price of XFOR common stock below $1 for 32 consecutive business days as of Aug 13, 2024.
X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings
Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.
X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones
Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.
X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway
Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.
Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).
On Aug 13, 2024, Nasdaq notified X4 that its common stock closing bid price was below $1.00 for 32 consecutive business days.
X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M
Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.
X4 reports positive Phase 2 mavorixafor data in chronic neutropenia; starts Phase 3 4WARD trial
100% (6/6) evaluable participants achieved target ANC increase (>500 cells/µL) at Months 3 and 6 on mavorixafor ± G-CSF.
X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025
Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.
X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome
Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.
X4 Pharma receives FDA approval for XOLREMDI (mavorixafor), first drug for WHIM syndrome
XOLREMDI approved for patients 12+ with WHIM syndrome to increase circulating neutrophils and lymphocytes.
FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr
XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.
X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30
Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.
X4 Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq letter on Nov 13, 2023 for non-compliance with minimum $1.00 bid price rule.
X4 Pharma: NDA accepted for mavorixafor in WHIM with PDUFA April 30, 2024; Q3 net loss $2.3M
FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome with Priority Review; PDUFA target April 30, 2024; eligible for Priority Review Voucher if approved.
FDA accepts X4's NDA for mavorixafor with Priority Review; PDUFA April 30, 2024
FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome (ages 12+) with Priority Review.
X4 Pharmaceuticals appoints industry veteran R. Keith Woods to Board of Directors
Woods appointed as independent Class II director effective Oct 16, 2023, term through 2025 annual meeting.
X4 Pharma submits NDA to FDA for mavorixafor in WHIM syndrome
Submission supported by positive Phase 3 4WHIM trial results; met primary and key secondary endpoints.
X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising
Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.
X4 Pharmaceuticals closes $115M loan facility with Hercules Capital; draws $22.5M initially
New $115M term loan facility with Hercules Capital; $32.5M refinanced, $22.5M drawn at closing.
X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome
42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.
X4 Pharma Q1 net loss $24.0M; cash $94.4M into Q2 2024; mavorixafor NDA on track
Net loss of $24.0M in Q1 2023 vs $22.0M in Q1 2022; R&D expenses $22.1M including $5.0M milestone accrual.
X4 Pharma FY2022 net loss $93.9M; WHIM trial success, NDA submission planned for H2 2023
Cash $123M as of Dec 31, 2022; funds operations into Q2 2024.
On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026.
On October 16, 2023, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Keith Woods as a member of the Company’s Board, effective immediately.
Derek Meisner provided X4 Pharmaceuticals, Inc. (the “Company”) with notice of his intent to resign from his position as Chief Legal Officer and Corporate Secretary of the Company, effective August 22, 2022, in order to pursue another opportunity.
On November 11, 2021, René Russo resigned from the Board of Directors
On October 14, 2021, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Francoise de Craecker as a member of the Company’s Board, effective immediately.
On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).
Max materiality 0.90 · Median 0.70 · Most common event other_material